These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35597120)

  • 21. Differential epitope prediction across diverse circulating variants of SARS-COV-2 in Brazil.
    Cavalcanti-Dantas VM; Fernandes B; Dantas PHLF; Uchoa GR; Mendes AF; Araújo Júnior WO; Castellano LRC; Fernandes AIV; Goulart LR; Oliveira RADS; Assis PAC; Souza JR; Morais CNL
    Comput Biol Chem; 2024 Oct; 112():108139. PubMed ID: 38972100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex.
    Bhattacharya M; Sharma AR; Mallick B; Sharma G; Lee SS; Chakraborty C
    Infect Genet Evol; 2020 Nov; 85():104587. PubMed ID: 33039603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular dynamic simulation suggests stronger interaction of Omicron-spike with ACE2 than wild but weaker than Delta SARS-CoV-2 can be blocked by engineered S1-RBD fraction.
    Santra D; Maiti S
    Struct Chem; 2022; 33(5):1755-1769. PubMed ID: 35966763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An
    Dar HA; Waheed Y; Najmi MH; Ismail S; Hetta HF; Ali A; Muhammad K
    J Immunol Res; 2020; 2020():8893483. PubMed ID: 33274246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in spike protein T cell epitopes of SARS-COV-2 variants: Plausible influence on vaccine efficacy.
    Sankaranarayanan S; Mohkhedkar M; Janakiraman V
    Biochim Biophys Acta Mol Basis Dis; 2022 Sep; 1868(9):166432. PubMed ID: 35568352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
    Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z
    Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioinformatics-based SARS-CoV-2 epitopes design and the impact of spike protein mutants on epitope humoral immunities.
    Sun Q; Huang Z; Yang S; Li Y; Ma Y; Yang F; Zhang Y; Xu F
    Immunobiology; 2022 Nov; 227(6):152287. PubMed ID: 36244092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.
    Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M
    Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering the immunogenic T-cell epitopes from spike protein of SARS-CoV-2 concerning the diverse population of India.
    Devi SS; Kardam V; Dubey KD; Dwivedi M
    J Biomol Struct Dyn; 2023 Apr; 41(7):2713-2732. PubMed ID: 35132938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an
    Kesarwani V; Gupta R; Vetukuri RR; Kushwaha SK; Gandhi S
    Front Immunol; 2021; 12():725240. PubMed ID: 34630400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.
    Oliveira SC; de Magalhães MTQ; Homan EJ
    Front Immunol; 2020; 11():587615. PubMed ID: 33193414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein.
    Jiang S; Wu S; Zhao G; He Y; Guo X; Zhang Z; Hou J; Ding Y; Cheng A; Wang B
    Emerg Microbes Infect; 2022 Dec; 11(1):730-740. PubMed ID: 35171086
    [No Abstract]   [Full Text] [Related]  

  • 33. Multiple epitope-based vaccine prediction against SARS-CoV-2 spike glycoprotein.
    Sirohi PR; Gupta J; Somvanshi P; Prajapati VK; Grover A
    J Biomol Struct Dyn; 2022 May; 40(8):3347-3358. PubMed ID: 33246394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework.
    Kumar N; Admane N; Kumari A; Sood D; Grover S; Prajapati VK; Chandra R; Grover A
    Sci Rep; 2021 Apr; 11(1):7653. PubMed ID: 33828130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19.
    Sadat SM; Aghadadeghi MR; Yousefi M; Khodaei A; Sadat Larijani M; Bahramali G
    Mol Biotechnol; 2021 May; 63(5):389-409. PubMed ID: 33625681
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Mitra D; Pandey J; Jain A; Swaroop S
    J Biomol Struct Dyn; 2022 Jul; 40(11):5189-5202. PubMed ID: 33403946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.
    Xu W; Wang M; Yu D; Zhang X
    Front Immunol; 2020; 11():565278. PubMed ID: 33013929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.
    Uttamrao PP; Sathyaseelan C; Patro LPP; Rathinavelan T
    Front Immunol; 2021; 12():692937. PubMed ID: 34497604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.
    Oyarzun P; Kashyap M; Fica V; Salas-Burgos A; Gonzalez-Galarza FF; McCabe A; Jones AR; Middleton D; Kobe B
    Front Immunol; 2021; 12():598778. PubMed ID: 33717077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-wide analysis of Indian SARS-CoV-2 genomes to identify T-cell and B-cell epitopes from conserved regions based on immunogenicity and antigenicity.
    Ghosh N; Sharma N; Saha I; Saha S
    Int Immunopharmacol; 2021 Feb; 91():107276. PubMed ID: 33385714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.